Comprehensive Stock Comparison
Compare Olema Pharmaceuticals, Inc. (OLMA) vs Genmab A/S (GMAB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | OLMA | Beta 0.43 vs GMAB's 0.61, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | OLMA | +453.8% vs GMAB's +29.8% |
| Efficiency (ROA) | GMAB | 93.6% ROA vs OLMA's -42.5%, ROIC 22.2% vs -46.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for women's cancers, particularly estrogen receptor-positive breast cancer. It currently generates no revenue from product sales — its funding comes from equity financing and potential future milestone payments from partnerships — and its financial model depends on advancing its lead candidate OP-1250 through clinical trials toward eventual commercialization. The company's key advantage lies in its novel dual-mechanism drug candidate that acts as both an estrogen receptor antagonist and degrader, potentially offering improved efficacy over existing therapies for resistant breast cancers.
Genmab is a biotechnology company that develops and commercializes antibody-based therapies for cancer and other serious diseases. It generates revenue primarily through product sales of its marketed antibodies like DARZALEX and teprotumumab, plus significant royalties and milestone payments from partnerships with pharmaceutical companies like Johnson & Johnson. The company's key advantage is its proprietary antibody technology platforms — particularly its DuoBody bispecific antibody platform — which enable it to create differentiated therapies with improved efficacy and safety profiles.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
OLMA leads in 2 of 6 categories (Financial Metrics, Total Returns). GMAB leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
GMAB and OLMA operate at a comparable scale, with $14.0B and $0 in trailing revenue.
| Metric | OLMAOlema Pharmaceuti… | GMABGenmab A/S |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.0B |
| EBITDAEarnings before interest/tax | -$165M | $5.3B |
| Net IncomeAfter-tax profit | -$150M | $6.6B |
| Free Cash FlowCash after capex | -$135M | $2.9B |
| Gross MarginGross profit ÷ Revenue | — | +94.3% |
| Operating MarginEBIT ÷ Revenue | — | +36.2% |
| Net MarginNet income ÷ Revenue | — | +46.8% |
| FCF MarginFCF ÷ Revenue | — | +20.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -81.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +18.3% | -66.7% |
Valuation Metrics
| Metric | OLMAOlema Pharmaceuti… | GMABGenmab A/S |
|---|---|---|
| Market CapShares × price | $1.7B | $18.1B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $16.7B |
| Trailing P/EPrice ÷ TTM EPS | -11.00x | 15.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 23.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.53x |
| EV / EBITDAEnterprise value multiple | — | 14.90x |
| Price / SalesMarket cap ÷ Revenue | — | 5.34x |
| Price / BookPrice ÷ Book value/share | 3.48x | 3.28x |
| Price / FCFMarket cap ÷ FCF | — | 15.15x |
Profitability & Efficiency
GMAB delivers a 114.2% return on equity — every $100 of shareholder capital generates $114 in annual profit, vs $-49 for OLMA. OLMA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to GMAB's 0.03x. On the Piotroski fundamental quality scale (0–9), GMAB scores 5/9 vs OLMA's 3/9, reflecting solid financial health.
| Metric | OLMAOlema Pharmaceuti… | GMABGenmab A/S |
|---|---|---|
| ROE (TTM)Return on equity | -48.8% | +114.2% |
| ROA (TTM)Return on assets | -42.5% | +93.6% |
| ROICReturn on invested capital | -46.5% | +22.2% |
| ROCEReturn on capital employed | -42.8% | +18.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.03x |
| Net DebtTotal debt minus cash | -$138M | -$8.8B |
| Cash & Equiv.Liquid assets | $139M | $9.9B |
| Total DebtShort + long-term debt | $1M | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | — | 48.21x |
Total Returns (with DRIP)
A $10,000 investment in GMAB five years ago would be worth $8,383 today (with dividends reinvested), compared to $5,986 for OLMA. Over the past 12 months, OLMA leads with a +453.8% total return vs GMAB's +29.8%. The 3-year compound annual growth rate (CAGR) favors OLMA at 80.7% vs GMAB's -7.8% — a key indicator of consistent wealth creation.
| Metric | OLMAOlema Pharmaceuti… | GMABGenmab A/S |
|---|---|---|
| YTD ReturnYear-to-date | -4.3% | -7.5% |
| 1-Year ReturnPast 12 months | +453.8% | +29.8% |
| 3-Year ReturnCumulative with dividends | +490.2% | -21.6% |
| 5-Year ReturnCumulative with dividends | -40.1% | -16.2% |
| 10-Year ReturnCumulative with dividends | -50.6% | +138.4% |
| CAGR (3Y)Annualised 3-year return | +80.7% | -7.8% |
Risk & Volatility
OLMA is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than GMAB's 0.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GMAB currently trades 83.1% from its 52-week high vs OLMA's 67.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OLMAOlema Pharmaceuti… | GMABGenmab A/S |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.43x | 0.61x |
| 52-Week HighHighest price in past year | $36.13 | $35.43 |
| 52-Week LowLowest price in past year | $2.86 | $17.24 |
| % of 52W HighCurrent price vs 52-week peak | +67.0% | +83.1% |
| RSI (14)Momentum oscillator 0–100 | 48.3 | 38.3 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.5M |
Analyst Outlook
Wall Street rates OLMA as "Buy" and GMAB as "Buy". Consensus price targets imply 79.3% upside for OLMA (target: $43) vs 37.6% for GMAB (target: $41).
| Metric | OLMAOlema Pharmaceuti… | GMABGenmab A/S |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $43.38 | $40.50 |
| # AnalystsCovering analysts | 7 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.5% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 20 | Feb 26 | Change |
|---|---|---|---|
| Olema Pharmaceutica… (OLMA) | 100 | 52.35 | -47.7% |
| Genmab A/S (GMAB) | 100 | 87 | -13.0% |
Genmab A/S (GMAB) returned -16% over 5 years vs Olema Pharmaceutica… (OLMA)'s -40%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Olema Pharmaceutica… (OLMA) | $0.00 | $0.00 | — |
| Genmab A/S (GMAB) | $1.1B | $21.5B | +1799.8% |
Genmab A/S's revenue grew from $1.1B (2015) to $21.5B (2024) — a 38.7% CAGR.
Chart 3P/E Ratio History — 8 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Genmab A/S (GMAB) | 9.3 | 1.7 | -81.7% |
Genmab A/S has traded in a 2x–9x P/E range over 8 years; current trailing P/E is ~15x.
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Olema Pharmaceutica… (OLMA) | -0.16 | -2.2 | -1275.0% |
| Genmab A/S (GMAB) | 1.26 | 12.14 | +863.5% |
Genmab A/S's EPS grew from $1.26 (2015) to $12.14 (2024) — a 29% CAGR.
Chart 5Free Cash Flow — 5 Years
Olema Pharmaceuticals, Inc. generated $-105M FCF in 2024 (-100% vs 2021). Genmab A/S generated $8B FCF in 2024 (+284% vs 2021).
OLMA vs GMAB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OLMA or GMAB a better buy right now?
Genmab A/S (GMAB) offers the better valuation at 15.4x trailing P/E (23.2x forward), making it the more compelling value choice. Analysts rate Olema Pharmaceuticals, Inc. (OLMA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OLMA or GMAB?
Over the past 5 years, Genmab A/S (GMAB) delivered a total return of -16.2%, compared to -40.1% for Olema Pharmaceuticals, Inc. (OLMA). A $10,000 investment in GMAB five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: GMAB returned +138.4% versus OLMA's -50.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OLMA or GMAB?
By beta (market sensitivity over 5 years), Olema Pharmaceuticals, Inc. (OLMA) is the lower-risk stock at 0.43β versus Genmab A/S's 0.61β — meaning GMAB is approximately 41% more volatile than OLMA relative to the S&P 500. On balance sheet safety, Olema Pharmaceuticals, Inc. (OLMA) carries a lower debt/equity ratio of 0% versus 3% for Genmab A/S — giving it more financial flexibility in a downturn.
04Which has better profit margins — OLMA or GMAB?
Genmab A/S (GMAB) is the more profitable company, earning 36.4% net margin versus 0.0% for Olema Pharmaceuticals, Inc. — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31.1% versus 0.0% for OLMA. At the gross margin level — before operating expenses — GMAB leads at 95.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is OLMA or GMAB more undervalued right now?
Analyst consensus price targets imply the most upside for OLMA: 79.3% to $43.38.
06Which pays a better dividend — OLMA or GMAB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OLMA or GMAB better for a retirement portfolio?
For long-horizon retirement investors, Olema Pharmaceuticals, Inc. (OLMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43)). Both have compounded well over 10 years (OLMA: -50.6%, GMAB: +138.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OLMA and GMAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OLMA is a small-cap quality compounder stock; GMAB is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.